Antibody-Drug Conjugates in Prostate Cancer: Where Are we?

Clin Genitourin Cancer. 2023 Feb;21(1):171-174. doi: 10.1016/j.clgc.2022.07.009. Epub 2022 Jul 23.

Abstract

Antibody-drug conjugates (ADCs) reflect a new promising approach in prostate cancer, even more so after the practice-changing results in other malignancies, either hematologic or solid. ADCs consist of monoclonal antibodies (mAb) targeted at specific antigens overly expressed on cancer cells compared to normal cells. A cytotoxic payload is attached to the mAb using a stable linker. In prostate cancer, PSMA, STEAP1, TROP2, CD46 and B7-H3 are antigens currently being studied as targets for ADCs. In this paper, we discuss the composition of ADCs and focus on their application and challenges as treatment options in prostate cancer.

Keywords: Antibody-drug conjugate; Monoclonal antibody; PSMA; Precision oncology; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antigens, Neoplasm / therapeutic use
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Immunoconjugates* / therapeutic use
  • Male
  • Neoplasms* / drug therapy
  • Oxidoreductases / therapeutic use
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / pathology

Substances

  • Immunoconjugates
  • Antineoplastic Agents
  • Antibodies, Monoclonal
  • STEAP1 protein, human
  • Antigens, Neoplasm
  • Oxidoreductases